RhumbLine Advisers’s GreenLight Biosciences Holdings, PBC Common Stock GRNA Stock Holding History

RhumbLine Advisers’s Portfolio GRNA Stock Details GRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-8,337	Closed	-$2.48K	–	4423
2023 Q2	$2.48K	Sell	8,337 -59,916	-88%	-$18.1K	﹤0.01%	4185
2023 Q1	$29K	Buy	68,253 +782	+1%	+$600	﹤0.01%	2926
2022 Q4	$80K	Buy	67,471 +21,937	+48%	+$35.7K	﹤0.01%	2918
2022 Q3	$106K	Buy	45,534 +32,493	+249%	+$85.1K	﹤0.01%	2997
2022 Q2	$29K	Buy	+13,041	New	+$90.4K	﹤0.01%	3072

RhumbLine Advisers's GRNA Position: Q3 2023 in Review

RhumbLine Advisers sold out of GreenLight Biosciences Holdings, PBC Common Stock (GRNA) in Q3 2023, closing a stake of 8,337 shares — an estimated $2.48K sold.

RhumbLine Advisers first reported a position in GRNA in Q2 2022 and held it in 5 quarters. The position peaked at $106K in Q3 2022. 0 funds tracked by Wall St. Rank hold GRNA as of Q3 2023.

RhumbLine Advisers reported no remaining GreenLight Biosciences Holdings, PBC Common Stock position as of Q3 2023 after selling out during the quarter.
RhumbLine Advisers sold 8,337 GreenLight Biosciences Holdings, PBC Common Stock shares in Q3 2023, an estimated $2.48K.
RhumbLine Advisers first reported a position in GreenLight Biosciences Holdings, PBC Common Stock in Q2 2022 and held it in 5 quarters.
RhumbLine Advisers's GreenLight Biosciences Holdings, PBC Common Stock position peaked at $106K in Q3 2022.
0 funds tracked by Wall St. Rank held GreenLight Biosciences Holdings, PBC Common Stock as of Q3 2023.

Based on RhumbLine Advisers's 13F filing for Q3 2023, filed 9 Nov 2023.